Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darm


-- Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, microbiome-based immuno-oncology therapy, and avelumab (BAVENCIO(®)), ... Lees verder

Bron: ANP Pers support
Tags:
Geplaatst: 14 jan 2020 - 08:47